A study by Charité researchers found that triple therapy restored CFTR channel function to 90% in children with cystic fibrosis, with effects more pronounced in younger children. The therapy improved lung function and quality of life in children as young as 2 years old, offering hope for early treatment in childhood.
Scientists at the University of Geneva have discovered that abnormal activation of connexin 43 disrupts cellular organisation and compromises airway integrity. By blocking connexin 43 activity, they restored cell orientation and prevented bacterial attachment.
A new wearable sticker system has been developed to simplify diagnostic sweat testing for cystic fibrosis, a genetic disorder affecting digestion and breathing. The innovative technology is reliably accurate and makes the test more accessible beyond specialized centers.
A multidisciplinary study has identified a novel biofilm regulatory protein called Biofilm Architecture Regulator (BatR) and its role in Pseudomonas aeruginosa infections. The discovery may lead to new targets for anti-infective treatments, including those for people with cystic fibrosis.
Researchers have identified a widespread source of error in a popular genome study method and created a machine-learning tool to correct it. PATTY uses machine learning to reduce artifacts while preserving real signals in noisy data, giving researchers a clearer view of gene activity control.
Researchers found that combining formoterol and methacholine speeds up mucociliary clearance, reducing chronic lung infections. The combination is safe and well-tolerated, offering a new approach to managing the disease.
Children's Hospital Colorado has pioneered a groundbreaking approach to treating cystic fibrosis before birth, resulting in reduced NICU stays and improved pancreatic function. The pioneering care model uses ETI therapy to improve lung health and offers seamless continuation of treatment after birth through breast milk.
A team of researchers identified multiple defects in macrophages that leave people with CF vulnerable to MABS infections. The study found that even the most effective CF drug doesn't boost macrophage's ability to kill MABS.
A study has mapped the development of lung damage in young children with cystic fibrosis, revealing that immune abnormalities begin early in life and persist despite current treatments. The research found that targeted anti-inflammatory therapies may be necessary alongside existing medications to prevent permanent lung damage.
A groundbreaking quadruple-organ transplant at UChicago Medicine has saved the life of a young woman with cystic fibrosis. The surgery, performed by a team of experts, successfully transplanted her liver, kidney, and two lungs, offering her a second chance at life.
A study coordinated by the University of Trento has identified a gene therapy for individuals with cystic fibrosis caused by a specific mutation, offering new hope for those currently dependent on drugs. The therapy uses advanced gene editing technology to correct the DNA mutation responsible for the disease.
The number of pediatric lung transplants is expected to decline as highly effective therapies for cystic fibrosis reduce the need for transplantation. Complex cases with multi-system disease and severe cardiopulmonary compromise are on the rise, requiring highly specialized teams and close collaboration.
New findings render antibiotic-resistant bacteria vulnerable by disabling individual resistance and cross-protection. This approach offers new possibilities for treating resistant infections associated with cystic fibrosis and may inform the treatment of a broad range of antibiotic-resistant infections.
Researchers found that macrophages from CF patients display a pre-activated inflammatory state and exhibit exaggerated activation of NF-κB signaling. The extracellular matrix also acts as a persistent inflammatory stimulus, driving lung inflammation persistence despite CFTR function restoration.
Researchers used base editing to correct the SCN8A gene mutation responsible for severe inherited epilepsy. The approach successfully eliminated or reduced seizures and improved brain function in lab mice, offering new hope for treating genetic epilepsies.
Engineers have refined a technology to edit individual genetic base pairs, reducing unintended edits and increasing safety for potential treatments. The new base editors could lead to better outcomes for some cystic fibrosis patients and more accurate models for drug testing.
A new study found that young adults with complex childhood-onset conditions experience longer hospital stays, higher readmission rates, and greater use of resources in adult hospitals. These patients account for 6.7% of young adult hospitalizations but occupy 10.7% of all hospital bed-days.
A multi-site study led by CU Anschutz researchers found that people with cystic fibrosis who start triple-drug therapy elexacaftor/tezacaftor/ivacaftor (ETI) can safely reduce many daily lung treatments while maintaining good health for years. The study showed a steady decline in the use of chronic respiratory therapies, including hype...
Researchers at California NanoSystems Institute discover how Pseudomonas aeruginosa uses mechanical sensing to detect and bind to sugar trails, forming deadly biofilms that are resistant to antibiotics. This breakthrough could lead to new treatments for cystic fibrosis patients and other biofilm-related infections.
Researchers at Carnegie Mellon University's Ren lab have developed AggreBots, microscale living robots made from human lung cells that can be controlled to deliver therapeutic or mechanical interventions. The biobots use cilia, nanoscopic hair-like propellers, for movement and can be programmed to perform specific tasks.
Researchers at UC San Diego have created a new genetic editing approach that uses small nuclear RNA base editing, which can modify the genetic code with greater precision and safety than CRISPR. This method has the potential to treat various diseases, including neurodegenerative, cardiovascular, and immune disorders.
Dr. Michael Welsh's research on cystic fibrosis paved the way for a triple-drug combination therapy that has transformed CF from a fatal condition into a manageable one for over 90% of patients. His work also revealed the function and 'broken' nature of the CFTR protein, laying the foundation for targeted therapies.
Researchers have identified a previously unknown organelle called the hemifusome that plays a crucial role in cellular sorting and recycling. This discovery could lead to targeted treatments for complex genetic disorders like Hermansky-Pudlak syndrome, which affects multiple systems in the body.
Researchers have made a breakthrough in understanding the molecular determinants of drug response in cystic fibrosis patients who are resistant to current treatments. By analyzing CFTR mutations, they found that some proteins can be 'corrected' and respond to FDA-approved corrector drugs.
Researchers at the University of Groningen discovered that mefloquine can enhance the effect of aminoglycosides to override faulty stop signals in proteins. This could lead to the development of new drugs tackling genetic diseases.
The updated guidelines call for uniform screening protocols in all states, recommending that IRT screening labs run twice a week and screen for all mutations known to cause cystic fibrosis. This can lead to earlier diagnosis and better treatment outcomes for newborns with the disease.
A new guideline recommends testing for all CF-causing gene variants, including those less common in people of color. Genetic sequencing can be used as an intermediate improvement strategy if not all variants are included in the panel. Early coordination between public health departments and specialists is crucial for timely diagnosis.
A new study reveals a previously unexplored mode of protein regulation in cystic fibrosis, opening up a target for future therapies. The research finds that CFTR proteins form clusters on cell membranes, which are disrupted in people with the condition.
Research suggests that CFTR modulators improve lung function during pregnancy and are likely safe for exposed babies. The study analyzed data from 307 pregnancies between 2010 and 2021 and found better maternal health outcomes for those using highly effective CFTR modulators.
A new gene therapy has been trialled in humans with cystic fibrosis, aiming to improve lung function and reduce exacerbations. The treatment, BI 3720931, works by inserting a functioning copy of the CFTR gene into patients' airways.
A Dartmouth-led study reveals that cystic fibrosis disrupts the maturation of the gut microbiome in infants, leading to a depletion of health-associated bacteria and potentially poor health outcomes. The study found that the microbiomes of infants with CF remained stunted or delayed in their development compared to healthy infants.
Researchers at TUM found that cystic fibrosis causes changes in the immune system as early as birth, leading to frequent inflammation and infections. These changes are not affected by CFTR modulator therapies.
The Lurie Children's hospital has launched a newborn screening awareness campaign, urging parents to contact their pediatrician if results are out of normal range. Timely diagnosis and early treatment are crucial for conditions like cystic fibrosis, where delays can lead to more severe disease.
Researchers have developed a rabbit model to study CF-related pancreatic endocrine pathology, offering new insights into the disease's pathophysiology. The model identifies an indeterminate glucose tolerance stage in young CF rabbits, mirroring early signs of diabetes progression in humans.
A team of researchers at Vanderbilt University has developed robotic sensory cilia that can monitor mucus conditions in human airways, detecting infection, obstruction, and disease severity. The technology leverages external magnetic fields to sense mucus viscosity and layer thickness, paving the way for real-time monitoring and early ...
Researchers found that reducing sialic acid levels on MUC5B mucin protein can alter its structure, leading to entangled polymers and impaired mucus transport. This study identifies a possible therapeutic strategy for treating cystic fibrosis and other muco-obstructive diseases.
A University at Buffalo psychiatrist has been awarded $3 million to focus on the mental health of children with cystic fibrosis. The study will evaluate national prevalence of mental health concerns in children under 12, identify best screening methods and characterize issues seen in treated children. Early identification and addressin...
A new study found that cystic fibrosis patients with more severe disease characteristics exhibit shorter leukocyte telomere length and greater LTL attrition. This association may accelerate aging and increase susceptibility to age-related diseases, emphasizing the importance of early CF diagnosis and timely therapeutic intervention.
Scientists from Spirovant Sciences describe a novel adeno-associated virus (AAV) gene therapy called SP-101 that has been optimized for efficient human airway cell transduction. After single dose inhaled delivery, the vector showed consistent expression of a functional and regulated shortened human CFTR minigene.
A study found that dogs with a gallbladder disease similar to human cystic fibrosis have impaired CFTR function, not a genetic mutation. This discovery could lead to new treatment targets and insights into the underlying causes of CF-like diseases.
Researchers at Broad Institute of MIT and Harvard have developed a gene-editing approach that efficiently corrects the most common mutation causing cystic fibrosis, found in 85% of patients. The new method precisely and durably corrects the mutation in human lung cells, restoring cell function to levels similar to Trikafta.
A recent observational study shows that the new treatment significantly improves the health status of school-aged children with cystic fibrosis. The results, published in the European Respiratory Journal, have been a game-changer for most patients.
A recent study mapped the evolution of Pseudomonas aeruginosa, a deadly bacterium that causes devastating infections in people with underlying lung conditions. The researchers found that almost seven in ten infections are caused by just 21 genetic clones, which have rapidly evolved and spread globally over the last 200 years.
Researchers have identified two distinct types of dysbioses in cystic fibrosis, which differ in their ecological organization and response to treatment. These findings suggest that antimicrobial drugs may be more effective in hierarchically organized microbiota, potentially leading to improved treatment outcomes for patients.
A new Dartmouth-led study has provided new insights into the therapeutic potential of bacteriophage therapy for treating diseases like cystic fibrosis. Researchers found that respiratory epithelial cells sense and respond to therapeutic phages, and interactions between phages and epithelial cells are heterogenous in nature.
A national survey of nearly 1,600 US parents found that most lack knowledge about newborn screening and cystic fibrosis, leading to difficulties in understanding abnormal test results. The study emphasizes the need for greater public awareness and support from healthcare teams to improve outcomes for infants with cystic fibrosis.
Despite therapy, cystic fibrosis patients still suffer from persistent respiratory infections due to unregulated cell signals. By studying lung cells, scientists found a disruption in TGF-β and Wnt pathways, leading to bacterial docking station formation.
University of Calgary researchers found that communication between the lungs and brain triggers symptoms of sickness, changing treatment approaches for respiratory infections and chronic conditions. The study also suggests targeting neurological pathways alongside antibiotics to combat infections.
Researchers found that secreted products from certain bacteria strains can reduce inflammation in gut-derived cell lines and improve airway health in mice with cystic fibrosis. The study suggests probiotics could be beneficial for kids with CF, providing a potential proof of concept.
Researchers have made a breakthrough in developing genetic treatments for hereditary conditions like cystic fibrosis and inherited vision loss. They created a new type of lipid nanoparticle, called Thio-lipids, that can deliver therapeutic payloads to the lungs and retina.
Researchers at the University of Pennsylvania have developed a new method to efficiently determine which lipid nanoparticles are likely to bind to the lungs, rather than the liver. This breakthrough enables targeted delivery of mRNA therapeutics beyond the liver, offering new hope for treatments of cystic fibrosis and lung cancer.
Researchers at University of Queensland have discovered a zinc pathway defect in immune cells of people with cystic fibrosis, leading to increased susceptibility to bacterial infections. The team identified a potential solution by restoring the macrophages' ability to kill bacteria with a zinc transport protein.
A ground-breaking study published in Nature Communications sheds light on the intricate mechanisms underlying the virulence of Aspergillus fumigatus, specifically focusing on the crucial role of mycotoxin gliotoxin production. The research team identified pivotal roles played by GliT oxidoreductase and GtmA methyltransferase in the sel...
Researchers have engineered a living material resembling human phlegm to study polymicrobial biofilms in cystic fibrosis patients. The material, which grows 3D biofilms in a controlled manner, will help experts understand how these structures form and develop effective treatments.
Researchers at the University of Iowa have discovered that rare lung cells called pulmonary ionocytes mediate chloride and water absorption in airway surfaces. This unexpected function challenges previous assumptions about cystic fibrosis treatment.
A University at Buffalo-led research team has developed molecules that can transport chloride ions across cell membranes, increasing airway surface liquid and restoring normal mucus clearance in cystic fibrosis cells. The synthetic anion binders offer a new potential treatment for the chronic disease.
Five lung stem cell variants dominate CF lungs, causing inflammation, fibrosis, and mucin secretion. CFTR modulators fail to suppress these inflammatory variants, suggesting they as key targets for new drugs.
A new NIH study found that high levels of certain minerals and metals in environmental water supplies may increase the risk of nontuberculous mycobacteria pulmonary infections in people with cystic fibrosis. The presence of sulfate, vanadium, and molybdenum was positively associated with increased incidence of lung infections.
The new guidelines aim to ensure all individuals with cystic fibrosis have access to regular exercise testing and individualized exercise advice. The document provides comprehensive recommendations and instructions for health professionals, addressing inconsistencies in previous testing and promoting improved treatment outcomes.
Researchers found that clinical strains of Aspergillus fumigatus differ significantly from environmental strains in amino acid synthesis. The fungus appears to shape the lung microbiome to its advantage, surviving on vital metabolites produced by other microorganisms.